Navigation Links
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Date:6/8/2009

German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease

BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented phase 2 clinical data of the BiTE(R) antibody blinatumomab (MT103) at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany, showing a high response rate in acute lymphoblastic leukemia (ALL) patients with minimal residual disease (MRD)(1). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells.

The patients included in this phase 2 clinical trial were in complete hematological remission following intense chemotherapy regimens, but retained a detectable level of ALL cancer cells in their bone marrow -- so called minimal residual disease (MRD). Various studies have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD.

The primary endpoint of the phase 2 study is MRD response within four cycles of treatment. MRD response is defined as the elimination of ALL cancer cells in patients with MRD below the limit of detection. The achievement of the primary endpoint requires that at least 22% of 21 patients have an MRD response. Currently, 13 of 16, or 81% of evaluated patients have shown an MRD response, thus qualifying the trial as having met its primary endpoint before the completion of the study. Patients in all subgroups responded to treatment with blinatumomab, including bcr-abl positive patients after failure
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
3. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... adolescents who suffer from sleep disturbance or habitual short ... to those who enjoy a good night,s sleep. The ... Sleep Medicine . , In a new study involving ... from Uppsala County, researchers from Uppsala University demonstrate that ... (less than 7 hours per day) increased the risk ...
(Date:9/23/2014)... Airbus Helicopters Inc. (AHI) is proud to announce that ... Vision Zero Aviation Safety Award recipient for development ... safety service the company provides the air medical industry. ... for Airbus Helicopters Inc., presented Protean CEO John Cornett ... Medical Transport Conference Annual Community Awards banquet Monday, Sept. ...
(Date:9/23/2014)... September 23, 2014 Visiting Nurse Association ... home health care, hospice and palliative care, and community-based ... the Opening Bell last week at the New York ... Jersey philanthropist and social entrepreneur to care for immigrant ... Group has always worked to meet the urgent healthcare ...
(Date:9/23/2014)... 23, 2014 Given the nondiscretionary ... Fruit and Vegetable Markets industry is ... prices benefited operators over the five years to ... preference and demographic trends, including a focus on ... per capita fruit and vegetable consumption declined at ...
(Date:9/23/2014)... health care in the early 20th century, helping ... But bacteria are also constantly outsmarting science, and ... more frequently. This week,s Speaking of Chemistry focuses ... discusses the prospects for new drugs. The episode ... your pills if you feel better? Check it ...
Breaking Medicine News(10 mins):Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4Health News:NJ's Largest Nonprofit Home Health Care Agency Joins Deutsche Bank to Ring New York Stock Exchange Opening Bell 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... A new report released,today by the national consumer rights ... this country,s dangerous government-approved drugs and,devices have been marketed ... made safer only after women filed lawsuits., The ... Drug Companies,Fail To Protect Women and How Lawsuits Save ...
... consumer survey finds that 94 percent of Americans would ... CINCINNATI, Oct. 29 P&G (NYSE: PG ) ... remove more than 99,percent of pharmaceutical compounds from America,s ... 96 percent with PUR pitchers.* According to a,2008 investigation ...
... Access to their Health,Information and the Ability to ... 29 CVS Caremark today announced,an extension to ... who utilize the company,s pharmacy benefit management services ... information,online. Consumers are now able to link their ...
... Site Drives Fight Against Childhood,Obesity by Providing Daily Content ... 29 Troy (Mich.) Chamber of Commerce,s,Helen eWards Committee ... Excellence, sponsored by Miller Canfield. The Danialle Karmanos,Work It ... best site in the,Social Impact category and was also ...
... tissues was detected by immunohistochemistry (IHC), Western blotting ... Its correlation Western blotting and RT-PCR. Livin positivity ... with tumor progression. Expression of Livin and VEGF ... the fourth clinical stage, expression of Livin and ...
... to eradicate fatal parasite; first vaccines delivered following major ... Melbourne researchers that could eradicate a fatal form of ... and could soon be commercially available thanks to multi-million ... causes 50 million tapeworm infections and 50,000 deaths from ...
Cached Medicine News:Health News:New Report Shows How Drug Industry Immunity Would Endanger Women 2Health News:PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers* 2Health News:PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers* 3Health News:PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers* 4Health News:CVS Caremark Partners with Google Health to Provide Consumers with Online Access to their Prescription History through Caremark.com 2Health News:CVS Caremark Partners with Google Health to Provide Consumers with Online Access to their Prescription History through Caremark.com 3Health News:Danialle Karmanos' Work It Out (DKWIO) Site Earns Recognition for Web Excellence 2Health News:A potential targets for the prevention or treatment of esophageal carcinoma 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
Medicine Products: